172 related articles for article (PubMed ID: 28733136)
1. Unexpected Bone Formation Produced by RANKL Blockade.
Portal-Núñez S; Mediero A; Esbrit P; Sánchez-Pernaute O; Largo R; Herrero-Beaumont G
Trends Endocrinol Metab; 2017 Oct; 28(10):695-704. PubMed ID: 28733136
[TBL] [Abstract][Full Text] [Related]
2. Are osteoclasts needed for the bone anabolic response to parathyroid hormone? A study of intermittent parathyroid hormone with denosumab or alendronate in knock-in mice expressing humanized RANKL.
Pierroz DD; Bonnet N; Baldock PA; Ominsky MS; Stolina M; Kostenuik PJ; Ferrari SL
J Biol Chem; 2010 Sep; 285(36):28164-73. PubMed ID: 20558734
[TBL] [Abstract][Full Text] [Related]
3. Implications of osteoblast-osteoclast interactions in the management of osteoporosis by antiresorptive agents denosumab and odanacatib.
Sims NA; Ng KW
Curr Osteoporos Rep; 2014 Mar; 12(1):98-106. PubMed ID: 24477416
[TBL] [Abstract][Full Text] [Related]
4. Role of RANK ligand and denosumab, a targeted RANK ligand inhibitor, in bone health and osteoporosis: a review of preclinical and clinical data.
Dempster DW; Lambing CL; Kostenuik PJ; Grauer A
Clin Ther; 2012 Mar; 34(3):521-36. PubMed ID: 22440513
[TBL] [Abstract][Full Text] [Related]
5. [The mechanism of anti-RANKL antibody in the treatment of metabolic bone diseases including osteoporosis - possible applications of anti-RANKL antibody to the treatment of cancer patients].
Yasuda H
Nihon Yakurigaku Zasshi; 2019; 153(1):11-15. PubMed ID: 30643086
[TBL] [Abstract][Full Text] [Related]
6. Denosumab, a fully human monoclonal antibody to RANKL, inhibits bone resorption and increases BMD in knock-in mice that express chimeric (murine/human) RANKL.
Kostenuik PJ; Nguyen HQ; McCabe J; Warmington KS; Kurahara C; Sun N; Chen C; Li L; Cattley RC; Van G; Scully S; Elliott R; Grisanti M; Morony S; Tan HL; Asuncion F; Li X; Ominsky MS; Stolina M; Dwyer D; Dougall WC; Hawkins N; Boyle WJ; Simonet WS; Sullivan JK
J Bone Miner Res; 2009 Feb; 24(2):182-95. PubMed ID: 19016581
[TBL] [Abstract][Full Text] [Related]
7. Is RANKL inhibition both anti-resorptive and anabolic in rheumatoid arthritis?
Sims NA; Romas E
Arthritis Res Ther; 2015 Nov; 17():328. PubMed ID: 26577945
[TBL] [Abstract][Full Text] [Related]
8. Clinical applications of RANK-ligand inhibition.
Romas E
Intern Med J; 2009 Feb; 39(2):110-6. PubMed ID: 19356186
[TBL] [Abstract][Full Text] [Related]
9. Bispecific Antibody Binding To RANKL and Osteonectin with Enhanced Localization to the Bone.
Chen JH; Lin CY; Chen YM; Tian WT; Chu HM; Chang TW
Mol Pharm; 2017 Nov; 14(11):4113-4120. PubMed ID: 28954509
[TBL] [Abstract][Full Text] [Related]
10. Denosumab: RANKL inhibition in the management of bone loss.
Hamdy NA
Drugs Today (Barc); 2008 Jan; 44(1):7-21. PubMed ID: 18301800
[TBL] [Abstract][Full Text] [Related]
11. Cross-talk between the interleukin-6 and prostaglandin E(2) signaling systems results in enhancement of osteoclastogenesis through effects on the osteoprotegerin/receptor activator of nuclear factor-{kappa}B (RANK) ligand/RANK system.
Liu XH; Kirschenbaum A; Yao S; Levine AC
Endocrinology; 2005 Apr; 146(4):1991-8. PubMed ID: 15618359
[TBL] [Abstract][Full Text] [Related]
12. Denosumab: targeting the RANKL pathway to treat rheumatoid arthritis.
Chiu YG; Ritchlin CT
Expert Opin Biol Ther; 2017 Jan; 17(1):119-128. PubMed ID: 27871200
[TBL] [Abstract][Full Text] [Related]
13. RANK ligand inhibition with denosumab for the management of osteoporosis.
Lewiecki EM
Expert Opin Biol Ther; 2006 Oct; 6(10):1041-50. PubMed ID: 16989586
[TBL] [Abstract][Full Text] [Related]
14. Caffeic acid 3,4-dihydroxy-phenethyl ester suppresses receptor activator of NF-κB ligand–induced osteoclastogenesis and prevents ovariectomy-induced bone loss through inhibition of mitogen-activated protein kinase/activator protein 1 and Ca2+–nuclear factor of activated T-cells cytoplasmic 1 signaling pathways.
Wu X; Li Z; Yang Z; Zheng C; Jing J; Chen Y; Ye X; Lian X; Qiu W; Yang F; Tang J; Xiao J; Liu M; Luo J
J Bone Miner Res; 2012 Jun; 27(6):1298-1308. PubMed ID: 22337253
[TBL] [Abstract][Full Text] [Related]
15. New insight into unexpected bone formation by denosumab.
Wang L; Huang B; Chen X; Su J
Drug Discov Today; 2020 Sep; ():. PubMed ID: 32916270
[TBL] [Abstract][Full Text] [Related]
16. [Treatment of bone metastasis by denosumab, the human monoclonal neutralizing antibody to RANKL].
Yoneda T
Nihon Rinsho; 2012 Dec; 70(12):2165-71. PubMed ID: 23259391
[TBL] [Abstract][Full Text] [Related]
17. [Anti-RANKL antibody].
Omiya T; Tanaka S
Nihon Rinsho; 2015 Oct; 73(10):1690-5. PubMed ID: 26529931
[TBL] [Abstract][Full Text] [Related]
18. Skeletal and extraskeletal actions of denosumab.
Sinningen K; Tsourdi E; Rauner M; Rachner TD; Hamann C; Hofbauer LC
Endocrine; 2012 Aug; 42(1):52-62. PubMed ID: 22581255
[TBL] [Abstract][Full Text] [Related]
19. Effect of RANKL-specific denosumab on osteoclast number and function: a potential friend or foe?
Tankó LB
Curr Opin Investig Drugs; 2007 Oct; 8(10):830-5. PubMed ID: 17907059
[TBL] [Abstract][Full Text] [Related]
20. Production of IL-7 is increased in ovariectomized mice, but not RANKL mRNA expression by osteoblasts/stromal cells in bone, and IL-7 enhances generation of osteoclast precursors in vitro.
Sato T; Watanabe K; Masuhara M; Hada N; Hakeda Y
J Bone Miner Metab; 2007; 25(1):19-27. PubMed ID: 17187190
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]